An interventional study of Ciprofloxacin 500 mg and Metronidazole 500 mg in Perianal Fistula, Perianal Abscess and Drain Abscess, sponsored by dr. IJM Han-Geurts. Status unknown at 11 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by dr. IJM Han-Geurts · Not applicable, Interventional, and Treatment
Rationale:
Perianal fistula is a burdening disease with an annual prevalence of 2/100.000 in the Dutch population. More than 90% of crypto-glandular fistulas originate from anorectal abscess. Despite adequate drainage of anorectal abscess up to 83% recurs or results in an anal fistula, the majority developing within 12 months. Up till now it is not common practice to routinely administer prophylactic antibiotics to prevent anal fistula development.\
Objective:
The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianal abscess results in less perianal fistulas.
Study design:
The study concerns a double-blind, placebo-controlled, randomized, multicenter trial with treatment of perianal abscess by surgical drainage alone or combined with antibiotic treatment. Patients will be accrued by all participating clinics. The design involves allocation of all appropriate consecutive patients with a primary occurrence of perianal abscess to surgical drainage followed by either antibiotics or placebo. Data will be analyzed on 'intention to treat' basis in case patients are not subjected to the randomized treatment modality.
Study population:
Men and women of 18 years and older who present for the first time with a perianal abscess.
Intervention (if applicable): The antibiotic group receives 7 days of oral metronidazole (500 mg every eight hours) and ciprofloxacin (500 mg every twelve hours) in addition to surgical drainage. The other group receives surgical drainage and postoperatively identical placebo tablets.
Main study parameters/endpoints:
Primary outcome measure is development of a perianal fistula. Secondary outcome measures are quality of life at 12 months measured with the EQ-5D-5L with Dutch rating. Further: in-hospital direct and indirect costs and out-of hospital postoperative costs, need of repeated drainage, patient related outcome (PRO) and clinical outcome measures.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
For this study, patients are asked to take part in a study comparing the addition of antibiotic treatment to surgical drainage of perianal abscess. Patients will not be burdened by extra hospital visits. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email and will take approximately 10 minutes each time.
dr. IJM Han-Geurts is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concomitant use of:
Two kinds of antibiotics: Ciprofloxacine 500mg 2dd \& Metronidazole 500mg 3dd
Drug: Ciprofloxacin 500 mg · Drug: Metronidazole 500 mg
Placebo tabletes
Drug: Placebo
One tablet of 500mg Ciprifloxacine, twice a day
One tablet of 500mg Metronidazole, three times a day
Placebo tablets
Perianal fistula at 1 year follow up
A perianal fistula is diagnosed based on findings from physical examination or by a telephone call after 12 months were the doctor asks for symptoms as serosanguinous discharge and pain. An external opening with or without serosanguilent discharge is considered a fistula. In case of doubt an endoanal ultrasonography or MRI is performed. So: yes/no fistula (dichotomous parameter)
Time frame: 1 year
Quality of life at 12 months measured with the EQ-5D-5L with Dutch rating.
The EQ-5D-5L is a generic Health Related Quality of Life (HRQoL) measure, which is broadly used in economic evaluation. The instrument examines a patient's HRQoL on the day of the interview. It consists of the EQ-5D-5L descriptive system and the EQ-Visual Analogue Scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses to the 5 items result in a patient's health state that can be transformed into an index score representing health-related quality of life, ranging between 0 (death) and 1 (full health). These index scores are combined with length of life to calculate the QALY. The EQ-VAS records the patient's self-rated health with endpoints labelled 'the best health you can imagine' at the top and 'the worst health you can imagine' at the bottom.
Time frame: 1 year
In-hospital direct and indirect costs and out-of hospital posteroperative costs
In-hospital direct and indirect costs (measured with iPCQ and iMCQ) and out-of hospital postoperative costs.
Time frame: 1 year
Need of repeated drainage
Time frame: 1 year
PROMs
Patient related outcome (PRO) are complaint reduction assessed by a proctology specific validated patient-related outcome measure, the proctoPROM(14). This was recently developed and validated at Proctos Clinic. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email with access to a web tool (Castor). If the patient does not have an email account, the questionnaires will be send the patients' home address, accompanied by a return envelope provided with postage stamps and the address of the hospital.
Time frame: 1 year
Day of discharge from hospital
Day of discharge from hospital;
Time frame: 1 year
Postoperative complications
Complications (postoperative bleeding, urinary retention requiring catheterisation, emergency reoperation, anal stenosis and fecal incontinence) including death and cause of death within 30 days will be reported using the Clavien-Dindo classification of surgical complications(15).
Time frame: 1 year
Recurrent abscess
(Recurrent) abscess within one year. Yes/no (dichotomous)
Time frame: 1 year
Duration of absence from work
Duration of absence from work. Amound of days is recorded (continuous scale)
Time frame: 1 year
Plan to share: Yes — A data management plan (DMP) will be composed containing the FAIR principles. Existing data will be used, and new data will be generated. Data are registered in an archive or repository and open access will be enabled. Results will be disclosed in a peer review medical journal to guarantee transparency. The study protocol was registered in an open access public trial registry before recruitment started.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Within one year after the last study visit of the last patient. Data will be availabe for 15 years.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2024, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ciprofloxacin · Metronidazole
dr. IJM Han-Geurts